{"gene":"HLA-DRA","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":2001,"finding":"CIITA coordinates multiple histone acetyltransferase activities at the HLA-DRA promoter: a CIITA mutant lacking its activation domain induced H4 but not H3 acetylation, indicating distinct HAT activities are required for each modification; H4 acetylation was mapped to Lys8.","method":"Chromatin immunoprecipitation (ChIP) time-course in CIITA-expressing cells; CIITA activation-domain deletion mutant; histone acetylation mapping","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vivo ChIP with time-course, CIITA mutant dissection, and specific residue mapping in a single rigorous study","pmids":["11429551"],"is_preprint":false},{"year":1991,"finding":"Two distinct nuclear factors bind the HLA-DRA X box region in B cells: RFX binds the X1 box but binds poorly to DRB beta-chain promoters, while a separate factor X2BP binds the X2 box of DRA with high affinity and recognizes a different subset of class II promoters.","method":"Gel electrophoretic mobility shift assays (EMSA) with B-cell nuclear extracts and DRA promoter oligonucleotides","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — EMSA with B-cell extracts, single lab, replicated across multiple class II promoters","pmids":["1956787"],"is_preprint":false},{"year":1992,"finding":"In vivo genomic footprinting of the HLA-DRA promoter demonstrated that IFN-γ induces class II expression in non-lymphoid glioblastoma cells by specifically up-regulating protein–DNA interactions at the X1 and X2 boxes, while leaving octamer, Y, and other contacts unchanged.","method":"In vivo genomic footprinting (DMS/ligation-mediated PCR) in B-cell lines, T-cell lines, and glioblastoma cells ± IFN-γ treatment","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct in vivo footprinting across multiple cell types with IFN-γ induction, single lab with rigorous controls","pmids":["1502171"],"is_preprint":false},{"year":1992,"finding":"Single base-pair substitutions in the HLA-DRA promoter demonstrated that W, X1, X2, and Y boxes each contribute to maximal B-cell expression, while W, X1, and X2 are specifically required for IFN-γ induction in fibroblasts; some mutations differentially affected B-cell vs. fibroblast expression, indicating cell-type-specific factor usage.","method":"Site-directed mutagenesis of DRA promoter linked to reporter gene; transient transfection in B cells and IFN-γ-treated fibroblasts; EMSA to assess DNA–protein interactions","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic single-bp mutagenesis plus EMSA, two cell types, single lab but multiple orthogonal methods","pmids":["1560213"],"is_preprint":false},{"year":1992,"finding":"Constitutive and IFN-γ-inducible transcription of HLA-DRA requires precise spacing between the S and X elements (any spacing change is not tolerated) and stereospecific helical alignment between X and Y elements; disruption of either constraint abolishes both constitutive B-cell expression and IFN-γ induction, implying a shared protein complex forms on all three elements.","method":"Spacing and helical-turn insertion/deletion mutants of DRA promoter; transient transfection reporter assays in B-cell lines and IFN-γ-treated fibroblasts","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic spacing/alignment mutagenesis with reporter assay, two cell types, multiple mutant series in one study","pmids":["1331098"],"is_preprint":false},{"year":1990,"finding":"X-box-binding proteins mediate both positive and negative transcriptional regulation of HLA-DRA: a positive W element (−135 to −117 bp) and a negative V element (−193 to −179 bp) upstream of the class II box both bind the same nuclear proteins that bind the X box, as shown by competition EMSA.","method":"5′ promoter deletions, substitution mutants, nuclease S1 protection assays, gel-mobility-shift assays with Raji nuclear extracts","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — deletion/substitution mutagenesis combined with EMSA competition, single lab, multiple complementary methods","pmids":["2120707"],"is_preprint":false},{"year":1989,"finding":"The trans-acting factor RF-X binds to the HLA-DRA promoter and its occupancy correlates with two prominent DNase I–hypersensitive sites in the class II promoter chromatin; these hypersensitive sites are absent in immunodeficient mutant B cells lacking RF-X binding, but are present in uninduced normal fibroblasts (which have normal RF-X binding), indicating RF-X binding is necessary but not sufficient for class II expression.","method":"DNase I hypersensitivity mapping; in vitro RF-X binding assays; comparison of normal B cells, class II–deficient mutant cells, and IFN-γ–induced fibroblasts","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — DNase I chromatin mapping correlated with RF-X binding in multiple cell types including patient-derived mutants; single lab but mechanistically informative","pmids":["2467188"],"is_preprint":false},{"year":1991,"finding":"Single base-pair substitutions across the HLA-DRA X1 box revealed the specific nucleotide positions required for RF-X binding; several substitutions severely reduced RF-X binding for both natural and recombinant RF-X with the same specificity, and positions important for high-affinity RF-X binding correlate with high levels of class II expression.","method":"EMSA with natural and recombinant RF-X protein; systematic single-bp substitutions across the DRA X1 box","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic mutagenesis with both natural and recombinant protein, EMSA, single lab but two forms of the factor used","pmids":["1903200"],"is_preprint":false},{"year":1991,"finding":"The W element (−143 to −123 bp) of the HLA-DRA promoter is a positive transcriptional regulator active in all DR+ cell types (not B-cell-specific), binding proteins W-B1 (ubiquitous) and W-B2 (lymphoid-specific); W/P-dependent activity parallels endogenous DRA transcription but tissue-restricted regulation is not accounted for solely by differential W-protein binding.","method":"Transient transfection reporter assays in multiple cell types; EMSA with W-element oligonucleotides; 5′ deletion and substitution analysis","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — reporter assay plus EMSA across multiple cell types, single lab","pmids":["1991973"],"is_preprint":false},{"year":1991,"finding":"The X-A DNA–protein complex containing proteins of ~22, 32, 82, and 92 kDa (UV cross-linked) is required for HLA-DRA X-box-dependent transcription; this complex is absent in the immunodeficient B-cell mutant 6.1.6 and in some (but not all) patient-derived class II–negative immunodeficiency cells.","method":"Transient transfection of DRA promoter-reporter constructs; EMSA; UV cross-linking of proteins to BrdU-substituted probe; comparison of normal and mutant cell extracts","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — UV cross-linking identifies complex components; multiple cell lines tested; single lab","pmids":["1904083"],"is_preprint":false},{"year":1992,"finding":"In primary astrocytes, IFN-γ regulation of HLA-DRA requires the S, X (specifically X1), and Y elements; IFN-γ induces a novel X-element–binding nuclear factor (IFNEX) in astrocytes that is distinct from previously described factors, suggesting IFNEX mediates IFN-γ–driven class II expression in this primary cell type.","method":"Site-specific mutagenesis of DRA promoter; transient transfection reporter assay in primary astrocytes; EMSA with nuclear extracts from IFN-γ–treated astrocytes","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — mutagenesis plus EMSA in primary (non-transformed) cell type, single lab","pmids":["1588050"],"is_preprint":false},{"year":1992,"finding":"TNF-α alone does not activate the HLA-DRA promoter in astrocytes but synergizes with IFN-γ via formation of a novel, slower-migrating DNA–protein complex (TIC-X) at the X element; W, X, and Y elements are all required for this TNF-α enhancement of IFN-γ–induced promoter activity.","method":"Transient transfection of DRA-CAT reporter in primary astrocytes ± IFN-γ and/or TNF-α; EMSA with nuclear extracts","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — reporter assay plus EMSA in primary astrocytes, single lab, two cytokine conditions","pmids":["1454841"],"is_preprint":false},{"year":1992,"finding":"T-cell activation induces strong HLA-DRA promoter activity from a proximal 43-bp TATTA-containing region in primary (non-transformed) T lymphocytes; mutation of the TATTA motif greatly reduces expression; addition of X and Y elements augments early activation response but paradoxically suppresses promoter function in already-activated DR+ T cells, revealing a cell-state-dependent switch.","method":"Transient transfection of DRA-CAT reporter constructs in primary human T lymphocytes stimulated by mitogens or antigens; TATTA mutagenesis","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — mutagenesis plus transfection in primary (non-transformed) cells, single lab","pmids":["1448091"],"is_preprint":false},{"year":1993,"finding":"hXBP-1, a b-ZIP transcription factor, regulates HLA-DRA through the X2 box; the hXBP-1 promoter itself contains an hX2 element identical to the X2 site in the DRA promoter, and two of four protein complexes binding the hXBP-1 hX2 site cross-compete with DRA X2-binding complexes, indicating an autoregulatory loop.","method":"EMSA cross-competition experiments; mutagenesis of hX2 site; DRA promoter mapping; hybrid cell mapping of hXBP-1 loci","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — EMSA cross-competition plus mutagenesis, single lab","pmids":["8349596"],"is_preprint":false},{"year":1995,"finding":"TRAX1, affinity-purified from HeLa nuclear extracts, is a novel X1-box-binding transcriptional activator of HLA-DRA (~40 kDa by UV cross-linking); it contacts the 5′ end of the X1 sequence (positions −109/−108) with hypersensitive sites at −114/−113/−97, a distinct footprint from RFX1, RFX, NF-Xc, and NF-X; it activates the HLA-DRA promoter in an in vitro transcription assay.","method":"Affinity purification from HeLa nuclear extracts; EMSA; UV cross-linking; methylation interference footprinting; in vitro transcription assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — affinity purification, in vitro transcription assay, UV cross-linking, and footprinting in a single study; single lab but multiple orthogonal methods","pmids":["7799935"],"is_preprint":false},{"year":1990,"finding":"In vitro transcription from the HLA-DRA promoter is completely dependent on the Y box; deletion of the Y box reduces transcription by 95%; the DRA octamer element does not utilize OTF-2 in a manner analogous to immunoglobulin promoters despite OTF-2 being present in B-cell extracts.","method":"Cell-free in vitro transcription assay using B-cell and HeLa nuclear extracts; 5′ deletion and internal deletion of Y box and octamer","journal":"Tissue antigens","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro transcription assay with deletion constructs, single lab, single method","pmids":["2278044"],"is_preprint":false},{"year":1994,"finding":"A 3′ untranslated region signal in HLA-DRA mRNA mediates nuclear retention; deletion of this region abrogates binding of compartmentalized nuclear/cytoplasmic proteins and releases HLA-DRA mRNA into the cytoplasm; the pattern of these mRNA-binding proteins differs between cell types (Raji vs. Ntera-2) and is modulated by retinoic acid.","method":"Transient transfection of DRA constructs with 3′ UTR deletions; nuclear/cytoplasmic RNA fractionation; RNA–protein binding assays with compartmentalized extracts","journal":"Journal of molecular biology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — transfection with deletion constructs plus fractionation and RNA-protein binding across multiple cell types, single lab","pmids":["8028004"],"is_preprint":false},{"year":2004,"finding":"Oct-1 represses IFN-γ inducibility of the endogenous HLA-DRA gene in Rb-defective tumor cells by occupying the HLA-DRA promoter and forming a repressive complex (DRAN) that blocks NF-Y access to the promoter; trichostatin A (HDAC inhibitor) converts the promoter to a transcriptionally competent state and displaces Oct-1.","method":"Oct-1 antisense transformants; chromatin immunoprecipitation (ChIP) of endogenous HLA-DRA promoter; in vitro DNA–protein binding (DRAN complex analysis); TSA treatment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP of endogenous gene plus antisense functional knockdown plus in vitro complex characterization, single lab, multiple orthogonal methods","pmids":["15105429"],"is_preprint":false},{"year":2006,"finding":"TLR-triggered (CpG-DNA and LPS) HLA-DRA expression in human B cells requires NF-κB activation at the DRA promoter in addition to CIITA; dominant-negative CIITA and CIITA siRNA show CIITA alone is insufficient for maximal TLR-induced expression, whereas NF-κB is dispensable for IFN-γ–induced class II expression.","method":"Dominant-negative CIITA expression; CIITA siRNA knockdown; NF-κB pathway inhibition; EMSA; chromatin immunoprecipitation (ChIP); promoter-reporter mutant analysis","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple approaches (DN mutant, siRNA, ChIP, EMSA, mutagenesis) in a single study, single lab","pmids":["16619292"],"is_preprint":false},{"year":2012,"finding":"Active transcription of HLA-DRA is accompanied by reduced nucleosome density at the proximal regulatory region and distinct distributions of histone acetylation and methylation marks throughout the gene; most modifications depend on RFX or CIITA binding to the proximal regulatory region; once established after IFN-γ induction, modifications persist through multiple cell divisions (epigenetic memory). Components of MLL methyltransferase (MLL1, ASH2L, RbBP5—some CIITA-independent) and GCN5-containing acetyltransferase complexes (ATAC and STAGA) are recruited across the gene.","method":"Dual crosslinking ChIP; ChIP-seq-like profiling of multiple histone marks; RFX and CIITA mutant B-cell lines; cell division tracking after stimulus removal; identification of complex components by ChIP","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP across multiple marks and mutant cell lines, multiple orthogonal approaches in a single study, single lab","pmids":["22701520"],"is_preprint":false},{"year":1998,"finding":"Recombinant HLA-DRA1*0101/DRB1*0401 heterodimers expressed in Drosophila S2 cells are functional: they present peptides to DRB1*0401-restricted T cells, bind peptide with similar specificity and affinity to human B-cell-derived molecules, and can be stabilized by high-affinity peptide; they show decreased N-linked glycosylation compared to human-derived molecules but retain antigen-presentation capacity.","method":"Drosophila S2 cell expression; flow cytometry; T-cell stimulation assay; SDS-PAGE stability assay ± peptide; peptide-binding assay","journal":"Tissue antigens","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution in heterologous system with functional T-cell assay and peptide-binding measurements; single lab but multiple orthogonal functional readouts","pmids":["9510368"],"is_preprint":false},{"year":1993,"finding":"Expression of HLA-DRA in thymic epithelial cells (without bone-marrow-derived APC expression) is sufficient to drive clonal deletion of superantigen-reactive T cells bearing TCRβ-V5 and -V11, and to induce tolerance to DR-alpha-derived processed peptide/I-Ab complexes, likely via clonal deletion.","method":"Transgenic mouse lines with cell-type-restricted HLA-DRA expression (thymic epithelium only vs. all APC); TCR Vβ repertoire analysis; T-cell tolerance assays","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — defined transgenic lines with restricted expression, multiple T-cell assays, clear genetic epistasis; single lab","pmids":["8100779"],"is_preprint":false},{"year":1993,"finding":"Transgenic DR-alpha/E-beta mixed isotype molecules efficiently interact with Mtv-7 superantigen to delete V-beta-6+ and V-beta-7+ T cells; deletion of V-beta-11+ T cells with Mtv-8/9 was less efficient than with H-2Ea transgenes, demonstrating that the alpha-chain identity influences superantigen interaction but the beta-chain identity is the critical determinant.","method":"HLA-DRA transgenic mice on various mouse Mtv-bearing backgrounds; TCR Vβ repertoire analysis by flow cytometry and Southern blot","journal":"Human immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — comparative transgenic analysis across multiple Mtv integrants; single lab","pmids":["8244778"],"is_preprint":false},{"year":1996,"finding":"The retinoblastoma protein (Rb) is required for IFN-γ induction of HLA-DRA (and other class II) mRNA in non-small-cell lung carcinoma cells; RB reconstitution rescues DRB inducibility but not DRA inducibility in H2009 subclones, explaining the lack of surface HLA-DR expression, and this Rb requirement operates independently of Rb's role in inhibiting apoptosis.","method":"RB reconstitution in RB-defective H2009 tumor cell subclones; Northern blot analysis of class II mRNAs; surface HLA-DR flow cytometry; CIITA mRNA analysis","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — RB reconstitution with multiple mRNA and surface protein readouts, comparison to a second tumor line; single lab","pmids":["8786310"],"is_preprint":false},{"year":2020,"finding":"A splice-acceptor variant (rs8084) in HLA-DRA mediates transcription of a short HLA-DRA isoform (sHLA-DRA) lacking 25 amino acids in the extracellular domain; molecular dynamics simulations predict structural refolding affecting stability and trafficking; experimentally, sHLA-DRA cannot reach the cell surface independently but is retained in the ER for degradation, yet can be transported to the membrane via binding to the peptide-binding site of canonical full-length HLA heterodimers.","method":"Splice-variant identification; molecular dynamics simulations; cellular fractionation/trafficking assays; co-expression with canonical HLA-DR heterodimers; flow cytometry","journal":"Immunology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — experimental trafficking assays plus MD simulations; single lab, multiple methods but MD is computational","pmids":["32986852"],"is_preprint":false},{"year":2022,"finding":"The short HLA-DRA isoform (sHLA-DRA) binds to the outer domain of the HLA-DR2 peptide-binding site via a loop region (residues R69–G83) exposed only in the short isoform; the critical residue F76 mediates this interaction (experimentally validated); sHLA-DRA allosterically modifies the peptide-binding pocket conformation of canonical HLA-DR2 heterodimers.","method":"Atomistic molecular dynamics simulations; mutational validation of F76 residue; functional binding assays","journal":"Archives of biochemistry and biophysics","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — MD simulations with experimental mutagenesis validation of critical residue; single lab","pmids":["35218721"],"is_preprint":false},{"year":2024,"finding":"Cuproptosis upregulates HLA-DRA expression at the transcriptional level in a dose-dependent manner in ccRCC cells by inducing reactive oxygen species (ROS) production; high HLA-DRA expression promotes chemokine (CCL5, CXCL9, CXCL10) expression in the tumor microenvironment, enhances CD4+ and CD8+ T-cell infiltration, and synergizes with anti-PD-1 immunotherapy to suppress tumor growth in vivo.","method":"In vitro cuproptosis induction in ccRCC cells; dose-response RT-PCR/Western blot for HLA-DRA; siRNA knockdown; chemokine ELISA; in vivo mouse tumor model with anti-PD-1 treatment; flow cytometry for T-cell infiltration","journal":"Pharmaceuticals (Basel, Switzerland)","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — in vitro mechanistic assays plus in vivo validation; single lab","pmids":["38931345"],"is_preprint":false},{"year":2026,"finding":"siRNA knockdown of HLA-DRA in human valvular interstitial cells (VICs) under osteogenic stimulation reduces mineral deposition, alkaline phosphatase (ALP) activity, and VIC proliferation, indicating HLA-DRA functionally drives osteogenic remodeling in vitro.","method":"siRNA knockdown of HLA-DRA in human VICs; osteogenic stimulation; Alizarin Red S staining; ALP activity assay; CCK-8 proliferation assay; RT-qPCR; Western blot","journal":"Journal of computer-aided molecular design","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single study, siRNA knockdown with cellular phenotype but no pathway placement beyond observation","pmids":["41721874"],"is_preprint":false},{"year":2026,"finding":"HLA-DRA overexpression in nasal mucosal epithelial cells increases radiosensitivity (reduced clonogenic survival, enhanced apoptosis, suppressed proliferation after irradiation) and elevates IFN-γ and IL-6 production, which activates JAK-STAT signaling; HLA-DRA knockout has the opposite effects, implicating HLA-DRA in regulating the JAK-STAT inflammatory pathway in irradiated epithelial cells.","method":"CRISPR/Cas9 HLA-DRA knockout and overexpression in nasal mucosal epithelial cells; X-ray irradiation; colony formation assay; CCK-8; flow cytometry (apoptosis); RT-qPCR; ELISA; Western blot for STAT phosphorylation","journal":"Zhonghua er bi yan hou tou jing wai ke za zhi","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — CRISPR KO and OE with multiple orthogonal assays and pathway identification; single lab","pmids":["41956771"],"is_preprint":false},{"year":1999,"finding":"Nuclear factor NF-Y binds to Y-box sequences in both the proximal promoter and the far-upstream region of HLA-DRA (Y′ box), as demonstrated by antibody supershift in gel-retardation assays; similar proteins bind to Y and Y′ boxes and to X and X′ boxes, supporting a model in which protein dimerization across these elements induces a DNA stem-loop bringing the far-upstream and proximal-promoter regions into proximity.","method":"DNase I footprinting; gel retardation (EMSA); antibody supershift for NF-Y identification","journal":"Biochimie","confidence":"Low","confidence_rationale":"Tier 3 / Weak — EMSA and footprinting identifying NF-Y at Y′ box; single lab, in vitro only, no functional (transcription) assay","pmids":["10385003"],"is_preprint":false}],"current_model":"HLA-DRA encodes the invariant α-chain of the HLA-DR class II MHC heterodimer; its transcription is controlled by a promoter module containing W, X1, X2, and Y cis-elements that recruit a hierarchy of trans-acting factors—including RF-X (occupying X1 and establishing chromatin accessibility), CIITA (coordinating H3/H4 histone acetyltransferase activities via MLL and GCN5/STAGA complexes), NF-Y (Y-box), Oct-1 (repressor in Rb-defective cells), NF-κB (required for TLR-mediated but not IFN-γ-mediated induction), and TRAX1 (a novel X1-binding activator)—with IFN-γ induction acting specifically by strengthening X-box protein–DNA interactions; a splice-acceptor variant generates a short isoform that is ER-retained and degraded but can reach the membrane by binding the outer peptide-binding site of canonical HLA-DR heterodimers, where it allosterically modifies the peptide-binding pocket."},"narrative":{"mechanistic_narrative":"HLA-DRA encodes the invariant α-chain of the HLA-DR class II MHC heterodimer, which pairs with a DRB β-chain to present peptide antigens to CD4+ T cells; recombinant DRA/DRB heterodimers reconstituted in heterologous cells bind peptide with native specificity and affinity and productively stimulate restricted T cells [PMID:9510368], and DRA-driven surface class II in thymic epithelium is sufficient to delete superantigen- and DR-peptide-reactive T cells, establishing a role in central tolerance [PMID:8100779]. The peptide-presenting α-chain identity modulates, but does not dictate, superantigen engagement, which is governed primarily by the β-chain [PMID:8244778]. The dominant theme of the corpus is transcriptional control of HLA-DRA through a conserved proximal module of W, X1, X2, and Y cis-elements that must remain precisely spaced and helically phased to assemble a single cooperative complex required for both constitutive and inducible expression [PMID:1560213, PMID:1331098]. RF-X occupies the X1 box, correlating with class II DNase I hypersensitivity and lost in class II–deficient immunodeficiency mutants, marking it as necessary but not sufficient for expression [PMID:2467188, PMID:1903200], while additional X-box-region factors (X2BP, hXBP-1, TRAX1) and the Y-box factor NF-Y act through the same module [PMID:1956787, PMID:8349596, PMID:7799935, PMID:2278044]. CIITA serves as the master coordinator, recruiting distinct histone acetyltransferase activities—directing H4 (Lys8) and H3 acetylation through separable domains—and, together with RFX, establishing reduced nucleosome density and heritable histone modification patterns across the locus [PMID:11429551, PMID:22701520]. IFN-γ induces expression specifically by strengthening protein–DNA contacts at the X1/X2 boxes [PMID:1502171], with cell-type-specific and stimulus-specific factors layered on top: an astrocyte IFN-γ–induced X-element factor and TNF-α synergy complex [PMID:1588050, PMID:1454841], an Rb requirement for DRA induction with Oct-1 acting as a repressor that excludes NF-Y in Rb-defective cells [PMID:15105429, PMID:8786310], and an NF-κB requirement specific to TLR-driven (but not IFN-γ–driven) induction [PMID:16619292]. Post-transcriptionally, a 3′ UTR signal mediates nuclear retention of HLA-DRA mRNA [PMID:8028004], and a splice-acceptor variant (rs8084) produces a short ER-retained isoform that lacks 25 extracellular residues and, rather than reaching the surface alone, binds the outer peptide-binding domain of canonical HLA-DR heterodimers via an exposed loop (F76) and allosterically reshapes the peptide-binding pocket [PMID:32986852, PMID:35218721]. In disease and tissue contexts, HLA-DRA expression is induced by cuproptosis-driven ROS and promotes T-cell-infiltrating chemokine production that synergizes with anti-PD-1 therapy in ccRCC [PMID:38931345], and modulates JAK-STAT inflammatory signaling and radiosensitivity in irradiated epithelial cells [PMID:41956771].","teleology":[{"year":1989,"claim":"Establishing which trans-acting factor licenses class II chromatin addressed why some cells fail to express HLA-DRA despite an intact promoter.","evidence":"DNase I hypersensitivity mapping and RF-X binding across normal B cells, class II–deficient mutants, and fibroblasts","pmids":["2467188"],"confidence":"High","gaps":["RF-X binding necessary but not sufficient for expression","additional factors enabling fibroblast/IFN-γ competence not identified"]},{"year":1990,"claim":"Dissecting the proximal promoter elements clarified that the Y box and X-box-binding proteins exert non-redundant positive and negative control over transcription.","evidence":"Cell-free in vitro transcription with Y-box/octamer deletions; competition EMSA mapping W and V elements to X-box-binding proteins","pmids":["2278044","2120707"],"confidence":"Medium","gaps":["identity of the shared X/W/V-binding proteins not resolved","octamer factor usage distinct from immunoglobulin promoters but mechanism unclear"]},{"year":1991,"claim":"Mapping the precise nucleotides and protein complexes at the X and W boxes defined the molecular grammar of factor recognition and linked binding affinity to expression level.","evidence":"Single-bp substitutions with natural and recombinant RF-X; EMSA distinguishing RFX (X1) from X2BP (X2); UV cross-linking of the X-A complex; W-element reporter/EMSA across cell types","pmids":["1903200","1956787","1904083","1991973"],"confidence":"Medium","gaps":["molecular identities of X-A complex subunits (22/32/82/92 kDa) not cloned","basis for tissue-restricted expression beyond differential binding unexplained"]},{"year":1992,"claim":"Systematic mutagenesis and IFN-γ footprinting resolved how a single cooperative complex on geometrically constrained elements drives both constitutive and inducible expression.","evidence":"Single-bp, spacing, and helical-phasing mutants in B cells and IFN-γ-treated fibroblasts; in vivo genomic footprinting ± IFN-γ; astrocyte IFNEX and TNF-α/IFN-γ synergy (TIC-X) EMSA","pmids":["1560213","1331098","1502171","1588050","1454841"],"confidence":"High","gaps":["IFNEX and TIC-X factors not molecularly identified","structural model of the X/Y stem-loop complex not determined"]},{"year":1993,"claim":"Functional and genetic tests established the protein product's role in antigen presentation, central tolerance, and the relative contribution of the α-chain to superantigen engagement.","evidence":"HLA-DRA transgenic mice with tissue-restricted expression; TCR Vβ repertoire and tolerance assays; hXBP-1 X2 cross-competition EMSA","pmids":["8100779","8244778","8349596"],"confidence":"Medium","gaps":["mechanism of thymic-epithelial clonal deletion incompletely defined","extent of hXBP-1 autoregulatory contribution to DRA in vivo unquantified"]},{"year":1995,"claim":"Affinity purification of a novel X1-binding activator extended the cast of transcription factors converging on the X box.","evidence":"Affinity purification from HeLa extracts; footprinting, UV cross-linking, and in vitro transcription showing TRAX1 activation","pmids":["7799935"],"confidence":"High","gaps":["TRAX1 gene identity and interplay with RFX/CIITA not established","in vivo requirement not tested"]},{"year":1996,"claim":"Identifying an Rb requirement and a 3′ UTR retention signal added a tumor-suppressor input and a post-transcriptional control layer to DRA regulation.","evidence":"RB reconstitution in RB-defective tumor cells with mRNA/surface readouts; 3′ UTR deletion with nuclear/cytoplasmic fractionation and RNA-protein binding","pmids":["8786310","8028004"],"confidence":"Medium","gaps":["molecular step at which Rb acts on DRA induction unclear","identity of the 3′ UTR-binding retention proteins unknown"]},{"year":2004,"claim":"Defining Oct-1 as a repressor that excludes NF-Y explained how Rb-defective cells silence inducible HLA-DRA.","evidence":"ChIP of endogenous promoter, Oct-1 antisense knockdown, DRAN complex analysis, and TSA treatment","pmids":["15105429"],"confidence":"High","gaps":["link between Rb status and Oct-1 recruitment not fully mechanistic","generality beyond Rb-defective tumor cells untested"]},{"year":2006,"claim":"Distinguishing TLR/NF-κB-dependent from IFN-γ-dependent induction showed CIITA is necessary but not sufficient for all activation routes.","evidence":"Dominant-negative CIITA, CIITA siRNA, NF-κB inhibition, ChIP, and EMSA in human B cells","pmids":["16619292"],"confidence":"High","gaps":["how NF-κB cooperates physically with CIITA/RFX at the promoter unresolved"]},{"year":2012,"claim":"Profiling chromatin state across the locus integrated RFX/CIITA factor binding with specific histone-modifying complexes and demonstrated heritable epigenetic memory of induction.","evidence":"Dual-crosslinking ChIP of multiple histone marks, RFX/CIITA mutant B-cell lines, MLL and GCN5 complex component detection, cell-division tracking","pmids":["22701520"],"confidence":"High","gaps":["mechanism maintaining marks through division not defined","CIITA-independent MLL recruitment route unclear"]},{"year":2020,"claim":"Characterizing a splice-acceptor variant revealed a non-canonical short isoform that piggybacks on full-length heterodimers and allosterically modulates peptide binding.","evidence":"Splice-variant identification, trafficking/fractionation assays, co-expression with canonical heterodimers, MD simulations, and F76 mutational validation","pmids":["32986852","35218721"],"confidence":"Medium","gaps":["functional/immunological consequence of pocket allostery in vivo not measured","structural claims rest substantially on MD simulation"]},{"year":2024,"claim":"Linking HLA-DRA to tumor immunity and tissue remodeling positioned its expression as a functional driver of inflammatory and disease phenotypes.","evidence":"Cuproptosis/ROS induction with chemokine and T-cell-infiltration readouts and anti-PD-1 in vivo; CRISPR KO/OE radiosensitivity and JAK-STAT analysis; siRNA osteogenesis assays","pmids":["38931345","41956771","41721874"],"confidence":"Medium","gaps":["whether phenotypes depend on antigen presentation versus non-canonical roles unresolved","osteogenesis finding is single low-confidence study without pathway placement"]},{"year":null,"claim":"The molecular identities of several X-box-region factors (X-A complex, IFNEX, TIC-X) and the structural architecture of the cooperative W/X/Y enhanceosome remain undefined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["no cloned identity for the UV-crosslinked X-A complex subunits","no high-resolution structure of the assembled promoter complex","in vivo contribution of TRAX1 and hXBP-1 not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[20,21]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[20,24]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[24]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[20,21]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,3,6,19]}],"complexes":["HLA-DR class II MHC heterodimer"],"partners":["RFX","CIITA","NFY","POU2F1","XBP1","RB1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P01903","full_name":"HLA class II histocompatibility antigen, DR alpha chain","aliases":["MHC class II antigen DRA"],"length_aa":254,"mass_kda":28.6,"function":"An alpha chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the beta chain HLA-DRB, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DR-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells (PubMed:15265931, PubMed:15322540, PubMed:17334368, PubMed:22327072, PubMed:24190431, PubMed:27591323, PubMed:29884618, PubMed:31495665, PubMed:8145819, PubMed:9075930). Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes (PubMed:8145819). In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins (PubMed:31495665). Presents peptides derived from intracellular proteins that are trapped in autolysosomes after macroautophagy, a mechanism especially relevant for T cell selection in the thymus and central immune tolerance (PubMed:17182262, PubMed:23783831). The selection of the immunodominant epitopes follows two processing modes: 'bind first, cut/trim later' for pathogen-derived antigenic peptides and 'cut first, bind later' for autoantigens/self-peptides (PubMed:25413013). The anchor residue at position 1 of the peptide N-terminus, usually a large hydrophobic residue, is essential for high affinity interaction with MHCII molecules (PubMed:8145819)","subcellular_location":"Cell membrane; Endoplasmic reticulum membrane; Early endosome membrane; Late endosome membrane; Lysosome membrane; Autolysosome membrane","url":"https://www.uniprot.org/uniprotkb/P01903/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HLA-DRA","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/HLA-DRA","total_profiled":1310},"omim":[{"mim_id":"620818","title":"MHC CLASS II DEFICIENCY 5; MHC2D5","url":"https://www.omim.org/entry/620818"},{"mim_id":"620815","title":"MHC CLASS II DEFICIENCY 2; MHC2D2","url":"https://www.omim.org/entry/620815"},{"mim_id":"615746","title":"ZXD FAMILY ZINC FINGER PROTEIN C; ZXDC","url":"https://www.omim.org/entry/615746"},{"mim_id":"613725","title":"SOLUTE CARRIER FAMILY 25, MEMBER 17; SLC25A27","url":"https://www.omim.org/entry/613725"},{"mim_id":"613335","title":"MEMBRANE-ASSOCIATED RING-CH FINGER PROTEIN 8; MARCHF8","url":"https://www.omim.org/entry/613335"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lung","ntpm":931.1},{"tissue":"lymphoid tissue","ntpm":1196.6}],"url":"https://www.proteinatlas.org/search/HLA-DRA"},"hgnc":{"alias_symbol":[],"prev_symbol":["HLA-DRA1"]},"alphafold":{"accession":"P01903","domains":[{"cath_id":"3.10.320.10","chopping":"31-101","consensus_level":"high","plddt":94.4372,"start":31,"end":101},{"cath_id":"2.60.40.10","chopping":"112-203","consensus_level":"high","plddt":96.7587,"start":112,"end":203}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P01903","model_url":"https://alphafold.ebi.ac.uk/files/AF-P01903-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P01903-F1-predicted_aligned_error_v6.png","plddt_mean":89.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HLA-DRA","jax_strain_url":"https://www.jax.org/strain/search?query=HLA-DRA"},"sequence":{"accession":"P01903","fasta_url":"https://rest.uniprot.org/uniprotkb/P01903.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P01903/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P01903"}},"corpus_meta":[{"pmid":"11429551","id":"PMC_11429551","title":"CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter.","date":"2001","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11429551","citation_count":152,"is_preprint":false},{"pmid":"1956787","id":"PMC_1956787","title":"Two B cell factors bind the HLA-DRA X box region and recognize different subsets of HLA class II promoters.","date":"1991","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/1956787","citation_count":73,"is_preprint":false},{"pmid":"1502171","id":"PMC_1502171","title":"In vivo footprint analysis of the HLA-DRA gene promoter: cell-specific interaction at the octamer site and up-regulation of X box binding by interferon gamma.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1502171","citation_count":68,"is_preprint":false},{"pmid":"25224099","id":"PMC_25224099","title":"HLA-DRA variants predict penicillin allergy in genome-wide fine-mapping genotyping.","date":"2014","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25224099","citation_count":65,"is_preprint":false},{"pmid":"1560213","id":"PMC_1560213","title":"Single base pair substitutions within the HLA-DRA gene promoter separate the functions of the X1 and X2 boxes.","date":"1992","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1560213","citation_count":64,"is_preprint":false},{"pmid":"20072847","id":"PMC_20072847","title":"Greater expression of TLR2, TLR4, and IL6 due to negative energy balance is associated with lower expression of HLA-DRA and HLA-A in bovine blood neutrophils after intramammary mastitis challenge with Streptococcus uberis.","date":"2010","source":"Functional & integrative genomics","url":"https://pubmed.ncbi.nlm.nih.gov/20072847","citation_count":59,"is_preprint":false},{"pmid":"1331098","id":"PMC_1331098","title":"Structural constraints within a trimeric transcriptional regulatory region. Constitutive and interferon-gamma-inducible expression of the HLA-DRA gene.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1331098","citation_count":50,"is_preprint":false},{"pmid":"24093602","id":"PMC_24093602","title":"Preliminary results in quantitation of HLA-DRA by real-time PCR: a promising approach to identify immunosuppression in sepsis.","date":"2013","source":"Critical care (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24093602","citation_count":48,"is_preprint":false},{"pmid":"2120707","id":"PMC_2120707","title":"X-box-binding proteins positively and negatively regulate transcription of the HLA-DRA gene through interaction with discrete upstream W and V elements.","date":"1990","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2120707","citation_count":46,"is_preprint":false},{"pmid":"1930684","id":"PMC_1930684","title":"Transcriptional regulation of the HLA-DRA gene.","date":"1991","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1930684","citation_count":39,"is_preprint":false},{"pmid":"2467188","id":"PMC_2467188","title":"Inherited immunodeficiency with a defect in a major histocompatibility complex class II promoter-binding protein differs in the chromatin structure of the HLA-DRA gene.","date":"1989","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2467188","citation_count":39,"is_preprint":false},{"pmid":"1588050","id":"PMC_1588050","title":"Usage of primary cells to delineate IFN-gamma-responsive DNA elements in the HLA-DRA promoter and to identify a novel IFN-gamma-enhanced nuclear factor.","date":"1992","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1588050","citation_count":39,"is_preprint":false},{"pmid":"1401907","id":"PMC_1401907","title":"Localization of IFN-gamma receptor in first trimester placenta to trophoblasts but lack of stimulation of HLA-DRA, -DRB, or invariant chain mRNA expression by IFN-gamma.","date":"1992","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1401907","citation_count":38,"is_preprint":false},{"pmid":"8786310","id":"PMC_8786310","title":"Apoptosis-independent retinoblastoma protein rescue of HLA class II messenger RNA IFN-gamma inducibility in non-small cell lung carcinoma cells. Lack of surface class II expression associated with a specific defect in HLA-DRA induction.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8786310","citation_count":38,"is_preprint":false},{"pmid":"1991973","id":"PMC_1991973","title":"The W element is a positive regulator of HLA-DRA transcription in various DR+ cell types.","date":"1991","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1991973","citation_count":36,"is_preprint":false},{"pmid":"1904083","id":"PMC_1904083","title":"Defective HLA DRA X box binding in the class II transactive transcription factor mutant 6.1.6 and in cell lines from class II immunodeficient patients.","date":"1991","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1904083","citation_count":36,"is_preprint":false},{"pmid":"16619292","id":"PMC_16619292","title":"Direct role of NF-kappaB activation in Toll-like receptor-triggered HLA-DRA expression.","date":"2006","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16619292","citation_count":35,"is_preprint":false},{"pmid":"1454841","id":"PMC_1454841","title":"Tumor necrosis factor alpha response elements in the HLA-DRA promoter: identification of a tumor necrosis factor alpha-induced DNA-protein complex in astrocytes.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1454841","citation_count":32,"is_preprint":false},{"pmid":"1903200","id":"PMC_1903200","title":"Regulatory factor-X binding to mutant HLA-DRA promoter sequences.","date":"1991","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/1903200","citation_count":31,"is_preprint":false},{"pmid":"35794593","id":"PMC_35794593","title":"HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC.","date":"2022","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35794593","citation_count":29,"is_preprint":false},{"pmid":"31617688","id":"PMC_31617688","title":"Insights into the polymorphism in HLA-DRA and its evolutionary relationship with HLA haplotypes.","date":"2019","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/31617688","citation_count":28,"is_preprint":false},{"pmid":"8586413","id":"PMC_8586413","title":"A novel Creb family gene telomeric of HLA-DRA in the HLA complex.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8586413","citation_count":25,"is_preprint":false},{"pmid":"12648283","id":"PMC_12648283","title":"Relative quantification of HLA-DRA1 and -DQA1 expression by real-time reverse transcriptase-polymerase chain reaction (RT-PCR).","date":"2003","source":"European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/12648283","citation_count":23,"is_preprint":false},{"pmid":"21067287","id":"PMC_21067287","title":"Multiple sclerosis risk markers in HLA-DRA, HLA-C, and IFNG genes are associated with sex-specific childhood leukemia risk.","date":"2010","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/21067287","citation_count":23,"is_preprint":false},{"pmid":"15105429","id":"PMC_15105429","title":"Oct-1 maintains an intermediate, stable state of HLA-DRA promoter repression in Rb-defective cells: an Oct-1-containing repressosome that prevents NF-Y binding to the HLA-DRA promoter.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15105429","citation_count":22,"is_preprint":false},{"pmid":"35543859","id":"PMC_35543859","title":"Expression of NOTCH1, NOTCH4, HLA-DMA and HLA-DRA is synergistically associated with T cell exclusion, immune checkpoint blockade efficacy and recurrence risk in ER-negative breast cancer.","date":"2022","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/35543859","citation_count":21,"is_preprint":false},{"pmid":"1448091","id":"PMC_1448091","title":"Activation of the HLA-DRA gene in primary human T lymphocytes: novel usage of TATA and the X and Y promoter elements.","date":"1992","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1448091","citation_count":20,"is_preprint":false},{"pmid":"25319953","id":"PMC_25319953","title":"HLA-DRA is associated with Parkinson's disease in Iranian population.","date":"2014","source":"International journal of immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/25319953","citation_count":19,"is_preprint":false},{"pmid":"30962219","id":"PMC_30962219","title":"Genetic Variation Within the HLA-DRA1 Gene Modulates Susceptibility to Type 1 Diabetes in HLA-DR3 Homozygotes.","date":"2019","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/30962219","citation_count":18,"is_preprint":false},{"pmid":"35208514","id":"PMC_35208514","title":"CD74 and HLA-DRA in Cervical Carcinogenesis: Potential Targets for Antitumour Therapy.","date":"2022","source":"Medicina (Kaunas, Lithuania)","url":"https://pubmed.ncbi.nlm.nih.gov/35208514","citation_count":18,"is_preprint":false},{"pmid":"1685491","id":"PMC_1685491","title":"Description of a polymorphism in the regulatory region of the HLA-DRA gene.","date":"1991","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1685491","citation_count":18,"is_preprint":false},{"pmid":"2278044","id":"PMC_2278044","title":"Functional analysis of cis-linked regulatory sequences in the HLA DRA promoter by transcription in vitro.","date":"1990","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/2278044","citation_count":17,"is_preprint":false},{"pmid":"9510368","id":"PMC_9510368","title":"Functional characterization of HLA-DRA1*0101/DRB1*0401 molecules expressed in Drosophila melanogaster cells.","date":"1998","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/9510368","citation_count":16,"is_preprint":false},{"pmid":"22701520","id":"PMC_22701520","title":"Multiple histone methyl and acetyltransferase complex components bind the HLA-DRA gene.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22701520","citation_count":16,"is_preprint":false},{"pmid":"8349596","id":"PMC_8349596","title":"The regulatory gene, hXBP-1, and its target, HLA-DRA, utilize both common and distinct regulatory elements and protein complexes.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8349596","citation_count":16,"is_preprint":false},{"pmid":"28881265","id":"PMC_28881265","title":"New variants near RHOJ and C2, HLA-DRA region and susceptibility to endometriosis in the Polish population-The genome-wide association study.","date":"2017","source":"European journal of obstetrics, gynecology, and reproductive biology","url":"https://pubmed.ncbi.nlm.nih.gov/28881265","citation_count":16,"is_preprint":false},{"pmid":"10527398","id":"PMC_10527398","title":"HLA-DMB gene and HLA-DRA promoter region polymorphisms in Australian multiple sclerosis patients.","date":"1999","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10527398","citation_count":15,"is_preprint":false},{"pmid":"24039160","id":"PMC_24039160","title":"Reaffirmation of GAK, but not HLA-DRA, as a Parkinson's disease susceptibility gene in a Taiwanese population.","date":"2013","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24039160","citation_count":15,"is_preprint":false},{"pmid":"22391069","id":"PMC_22391069","title":"HLA-DRA polymorphisms associated with risk of nasal polyposis in asthmatic patients.","date":"2012","source":"American journal of rhinology & allergy","url":"https://pubmed.ncbi.nlm.nih.gov/22391069","citation_count":15,"is_preprint":false},{"pmid":"28131168","id":"PMC_28131168","title":"HLA-DRA/HLA-DRB5 polymorphism affects risk of sporadic ALS and survival in a southwest Chinese cohort.","date":"2016","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28131168","citation_count":13,"is_preprint":false},{"pmid":"8420827","id":"PMC_8420827","title":"T-cell repertoire in a strain of transgenic C57BL/6 mice with the HLA-DRA gene on the X-chromosome.","date":"1993","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/8420827","citation_count":13,"is_preprint":false},{"pmid":"8244778","id":"PMC_8244778","title":"Mouse mammary tumor virus-mediated T-cell receptor negative selection in HLA-DRA transgenic mice.","date":"1993","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8244778","citation_count":12,"is_preprint":false},{"pmid":"1721044","id":"PMC_1721044","title":"Tissue-specific expression of the HLA-DRA gene in transgenic mice.","date":"1991","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/1721044","citation_count":11,"is_preprint":false},{"pmid":"8028004","id":"PMC_8028004","title":"Control of nucleo-cytoplasmic HLA-DRA mRNA partitioning by interaction of a retention signal with compartmentalized proteins.","date":"1994","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8028004","citation_count":11,"is_preprint":false},{"pmid":"8100779","id":"PMC_8100779","title":"Restricted expression of transgenic HLA-DRA gene in thymic epithelial cells and its role in acquisition of T cell tolerance to self-superantigens and processed DR alpha-derived peptide.","date":"1993","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8100779","citation_count":11,"is_preprint":false},{"pmid":"7799935","id":"PMC_7799935","title":"Affinity enrichment and functional characterization of TRAX1, a novel transcription activator and X1-sequence-binding protein of HLA-DRA.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7799935","citation_count":10,"is_preprint":false},{"pmid":"38931345","id":"PMC_38931345","title":"Improved Immunotherapy Outcomes via Cuproptosis Upregulation of HLA-DRA Expression: Promoting the Aggregation of CD4+ and CD8+T Lymphocytes in Clear Cell Renal Cell Carcinoma.","date":"2024","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/38931345","citation_count":9,"is_preprint":false},{"pmid":"7784170","id":"PMC_7784170","title":"Sequencing of an upstream region of the human HLA-DRA gene containing X' and Y' boxes.","date":"1995","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/7784170","citation_count":9,"is_preprint":false},{"pmid":"1754710","id":"PMC_1754710","title":"Transcriptional regulation of HLA-DRA gene.","date":"1991","source":"Research in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1754710","citation_count":8,"is_preprint":false},{"pmid":"36132072","id":"PMC_36132072","title":"HLA-DRA Gene Polymorphisms Are Associated with Graves' Disease as an Autoimmune Thyroid Disease.","date":"2022","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/36132072","citation_count":8,"is_preprint":false},{"pmid":"34311991","id":"PMC_34311991","title":"Tri-SNP polymorphism in the intron of HLA-DRA1 affects type 1 diabetes susceptibility in the Finnish population.","date":"2021","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34311991","citation_count":8,"is_preprint":false},{"pmid":"9187677","id":"PMC_9187677","title":"HLA-DRA promoter polymorphism and diversity generation within the immune system.","date":"1997","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9187677","citation_count":7,"is_preprint":false},{"pmid":"28862321","id":"PMC_28862321","title":"Expression of HLA-DRA and CD74 mRNA in whole blood during the course of complicated and uncomplicated Staphylococcus aureus bacteremia.","date":"2017","source":"Microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28862321","citation_count":6,"is_preprint":false},{"pmid":"33178870","id":"PMC_33178870","title":"Analysis of Single Nucleotide Polymorphisms in HLA-DRA, IL2RA , and HMGB1 Genes in Multiple Sclerosis.","date":"2020","source":"Reports of biochemistry & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/33178870","citation_count":6,"is_preprint":false},{"pmid":"35895219","id":"PMC_35895219","title":"Genetic polymorphism of HLA-DRA and alcohol consumption affect hepatitis development in the Korean population.","date":"2022","source":"Genes & genomics","url":"https://pubmed.ncbi.nlm.nih.gov/35895219","citation_count":4,"is_preprint":false},{"pmid":"12445311","id":"PMC_12445311","title":"The HLA-DRA*0102 allele: correct nucleotide sequence and associated HLA haplotypes.","date":"2002","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/12445311","citation_count":4,"is_preprint":false},{"pmid":"27073595","id":"PMC_27073595","title":"Association analysis of HLA-DRA in Chinese patients with sporadic Parkinson's disease.","date":"2015","source":"International journal of physiology, pathophysiology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27073595","citation_count":4,"is_preprint":false},{"pmid":"32986852","id":"PMC_32986852","title":"A splice acceptor variant in HLA-DRA affects the conformation and cellular localization of the class II DR alpha-chain.","date":"2020","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32986852","citation_count":4,"is_preprint":false},{"pmid":"10385003","id":"PMC_10385003","title":"Analysis of the human HLA-DRA gene upstream region: evidence for a stem-loop array directed by nuclear factors.","date":"1999","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/10385003","citation_count":4,"is_preprint":false},{"pmid":"9378957","id":"PMC_9378957","title":"In vitro and in vivo evidence for high frequency of I-Ab-reactive CD4+ T cells in HLA-DQ or HLA-DRA transgenic mice lacking endogenous MHC class I and/or class II expression.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9378957","citation_count":4,"is_preprint":false},{"pmid":"35981747","id":"PMC_35981747","title":"Possible Relationship between the HLA-DRA1 Intron Haplotype of Three Single-Nucleotide Polymorphisms in Intron 1 of the HLA-DRA1 Gene and Autoantibodies in Children at Increased Genetic Risk for Autoimmune Type 1 Diabetes.","date":"2022","source":"ImmunoHorizons","url":"https://pubmed.ncbi.nlm.nih.gov/35981747","citation_count":3,"is_preprint":false},{"pmid":"22890421","id":"PMC_22890421","title":"Common variants in HLA-DRA gene are associated with alcohol dependence in two Caucasian samples.","date":"2012","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/22890421","citation_count":3,"is_preprint":false},{"pmid":"38942763","id":"PMC_38942763","title":"Changes in expression of VGF, SPECC1L, HLA-DRA and RANBP3L act with APOE E4 to alter risk for late onset Alzheimer's disease.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/38942763","citation_count":3,"is_preprint":false},{"pmid":"16889686","id":"PMC_16889686","title":"Korean BAC library construction and characterization of HLA-DRA, HLA-DRB3.","date":"2006","source":"Journal of biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16889686","citation_count":3,"is_preprint":false},{"pmid":"34402606","id":"PMC_34402606","title":"Identification of three novel HLA-DRA alleles by next-generation sequencing.","date":"2021","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/34402606","citation_count":2,"is_preprint":false},{"pmid":"40072812","id":"PMC_40072812","title":"Effects of HLA-DRA, HLA-DQA1 and IL-6 Gene Variations to Glatiramer Acetate Resistance in Multiple Sclerosis Patients.","date":"2025","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40072812","citation_count":2,"is_preprint":false},{"pmid":"15955077","id":"PMC_15955077","title":"Modular usage of the HLA-DRA promoter in extra-hematopoietic and hematopoietic cell types of transgenic mice.","date":"2005","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/15955077","citation_count":2,"is_preprint":false},{"pmid":"19280058","id":"PMC_19280058","title":"Technological advances in the study of HLA-DRA promoter regulation: extending the functions of CIITA, Oct-1, Rb, and RFX.","date":"2009","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/19280058","citation_count":2,"is_preprint":false},{"pmid":"41721874","id":"PMC_41721874","title":"Single-nucleus and machine-learning integration identifies HLA-DRA and FTL as immune-metabolic axes and traditional Chinese medicine-targetable hubs in calcific aortic valve disease.","date":"2026","source":"Journal of computer-aided molecular design","url":"https://pubmed.ncbi.nlm.nih.gov/41721874","citation_count":2,"is_preprint":false},{"pmid":"35218721","id":"PMC_35218721","title":"A short HLA-DRA isoform binds the HLA-DR2 heterodimer on the outer domain of the peptide-binding site.","date":"2022","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/35218721","citation_count":1,"is_preprint":false},{"pmid":"32253955","id":"PMC_32253955","title":"The rs3129882/rs4248166 in HLA-DRA and rs34372695 in SYT11 are not associated with sporadic Parkinson's disease in Central Chinese population.","date":"2020","source":"The International journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32253955","citation_count":1,"is_preprint":false},{"pmid":"40643781","id":"PMC_40643781","title":"Association of HLA-DRA, HLA-DQA1, and IL-6 gene variations with susceptibility to multiple sclerosis.","date":"2025","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/40643781","citation_count":0,"is_preprint":false},{"pmid":"41232153","id":"PMC_41232153","title":"Role of HLA-DRA-CREB3L4 regulatory axis in the pathogenesis of ovarian endometriosis: Inhibition of CREB3L4 expression by HLA-DRA increases the risk of disease.","date":"2025","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41232153","citation_count":0,"is_preprint":false},{"pmid":"41627183","id":"PMC_41627183","title":"Polymorphisms in intron 1 of HLA-DRA differentially associate with type 1 diabetes and celiac disease and implicate involvement of complement system genes C4A and C4B.","date":"2026","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/41627183","citation_count":0,"is_preprint":false},{"pmid":"38168398","id":"PMC_38168398","title":"The Human Brainome: changes in expression of VGF, SPECC1L, HLA-DRA and RANBP3L act with APOE E4 to alter risk for late onset Alzheimer's disease.","date":"2023","source":"Research square","url":"https://pubmed.ncbi.nlm.nih.gov/38168398","citation_count":0,"is_preprint":false},{"pmid":"41956771","id":"PMC_41956771","title":"[Study on mechanism underlying the role of HLA-DRA in promoting radiation-induced sinusitis].","date":"2026","source":"Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery","url":"https://pubmed.ncbi.nlm.nih.gov/41956771","citation_count":0,"is_preprint":false},{"pmid":"14612968","id":"PMC_14612968","title":"Identification of a novel DNase I hypersensitive site within the far upstream region of the human HLA-DRA gene.","date":"2003","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/14612968","citation_count":0,"is_preprint":false},{"pmid":"1534306","id":"PMC_1534306","title":"[Functional expression of xenogenic mixed isotype molecule, DR alpha E beta, in transgenic mice with HLA-DRA gene on X chromosome].","date":"1992","source":"Fukuoka igaku zasshi = Hukuoka acta medica","url":"https://pubmed.ncbi.nlm.nih.gov/1534306","citation_count":0,"is_preprint":false},{"pmid":"22358954","id":"PMC_22358954","title":"Methylation state of the human HLA-DRa gene in transgenic mice.","date":"1991","source":"Cytotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/22358954","citation_count":0,"is_preprint":false},{"pmid":"41989255","id":"PMC_41989255","title":"Identification of the Novel HLA-DRA*01:20 Allele by Single Molecule, Real-Time DNA Sequencing.","date":"2026","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/41989255","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.09.11.675642","title":"Exhausted-like effector CD8 T cells mediate immune-stromal interactions at mucosal Chronic Graft-versus-Host Disease onset","date":"2025-09-16","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.11.675642","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.08.18.670793","title":"Spatial and Single-Cell Dissection of Fibroblast Subpopulation Reprogramming Driving Stromal Collapse in Breast Cancer Lymph Node Metastasis","date":"2025-08-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.18.670793","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.08.29.25334740","title":"Unraveling the Single-Cell Spatial Landscapes of Melanoma Brain Metastases","date":"2025-09-02","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.29.25334740","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.08.08.24311619","title":"Circulating pancreatic enzyme levels are a causal biomarker of type 1 diabetes","date":"2024-08-09","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.08.24311619","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.08.22.609211","title":"Remodelling of the glycome of B-cell precursor acute lymphoblastic leukemia cells developing drug-tolerance","date":"2024-08-23","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.22.609211","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.07.27.24311104","title":"Dual site proteomic analyses reveal potential drug targets for cardiovascular disease","date":"2024-07-29","source":"bioRxiv","url":"https://doi.org/10.1101/2024.07.27.24311104","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43169,"output_tokens":7859,"usd":0.123696,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17550,"output_tokens":4399,"usd":0.098863,"stage2_stop_reason":"end_turn"},"total_usd":0.222559,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"CIITA coordinates multiple histone acetyltransferase activities at the HLA-DRA promoter: a CIITA mutant lacking its activation domain induced H4 but not H3 acetylation, indicating distinct HAT activities are required for each modification; H4 acetylation was mapped to Lys8.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) time-course in CIITA-expressing cells; CIITA activation-domain deletion mutant; histone acetylation mapping\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vivo ChIP with time-course, CIITA mutant dissection, and specific residue mapping in a single rigorous study\",\n      \"pmids\": [\"11429551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Two distinct nuclear factors bind the HLA-DRA X box region in B cells: RFX binds the X1 box but binds poorly to DRB beta-chain promoters, while a separate factor X2BP binds the X2 box of DRA with high affinity and recognizes a different subset of class II promoters.\",\n      \"method\": \"Gel electrophoretic mobility shift assays (EMSA) with B-cell nuclear extracts and DRA promoter oligonucleotides\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — EMSA with B-cell extracts, single lab, replicated across multiple class II promoters\",\n      \"pmids\": [\"1956787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"In vivo genomic footprinting of the HLA-DRA promoter demonstrated that IFN-γ induces class II expression in non-lymphoid glioblastoma cells by specifically up-regulating protein–DNA interactions at the X1 and X2 boxes, while leaving octamer, Y, and other contacts unchanged.\",\n      \"method\": \"In vivo genomic footprinting (DMS/ligation-mediated PCR) in B-cell lines, T-cell lines, and glioblastoma cells ± IFN-γ treatment\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in vivo footprinting across multiple cell types with IFN-γ induction, single lab with rigorous controls\",\n      \"pmids\": [\"1502171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Single base-pair substitutions in the HLA-DRA promoter demonstrated that W, X1, X2, and Y boxes each contribute to maximal B-cell expression, while W, X1, and X2 are specifically required for IFN-γ induction in fibroblasts; some mutations differentially affected B-cell vs. fibroblast expression, indicating cell-type-specific factor usage.\",\n      \"method\": \"Site-directed mutagenesis of DRA promoter linked to reporter gene; transient transfection in B cells and IFN-γ-treated fibroblasts; EMSA to assess DNA–protein interactions\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic single-bp mutagenesis plus EMSA, two cell types, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"1560213\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Constitutive and IFN-γ-inducible transcription of HLA-DRA requires precise spacing between the S and X elements (any spacing change is not tolerated) and stereospecific helical alignment between X and Y elements; disruption of either constraint abolishes both constitutive B-cell expression and IFN-γ induction, implying a shared protein complex forms on all three elements.\",\n      \"method\": \"Spacing and helical-turn insertion/deletion mutants of DRA promoter; transient transfection reporter assays in B-cell lines and IFN-γ-treated fibroblasts\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic spacing/alignment mutagenesis with reporter assay, two cell types, multiple mutant series in one study\",\n      \"pmids\": [\"1331098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"X-box-binding proteins mediate both positive and negative transcriptional regulation of HLA-DRA: a positive W element (−135 to −117 bp) and a negative V element (−193 to −179 bp) upstream of the class II box both bind the same nuclear proteins that bind the X box, as shown by competition EMSA.\",\n      \"method\": \"5′ promoter deletions, substitution mutants, nuclease S1 protection assays, gel-mobility-shift assays with Raji nuclear extracts\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — deletion/substitution mutagenesis combined with EMSA competition, single lab, multiple complementary methods\",\n      \"pmids\": [\"2120707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"The trans-acting factor RF-X binds to the HLA-DRA promoter and its occupancy correlates with two prominent DNase I–hypersensitive sites in the class II promoter chromatin; these hypersensitive sites are absent in immunodeficient mutant B cells lacking RF-X binding, but are present in uninduced normal fibroblasts (which have normal RF-X binding), indicating RF-X binding is necessary but not sufficient for class II expression.\",\n      \"method\": \"DNase I hypersensitivity mapping; in vitro RF-X binding assays; comparison of normal B cells, class II–deficient mutant cells, and IFN-γ–induced fibroblasts\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — DNase I chromatin mapping correlated with RF-X binding in multiple cell types including patient-derived mutants; single lab but mechanistically informative\",\n      \"pmids\": [\"2467188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Single base-pair substitutions across the HLA-DRA X1 box revealed the specific nucleotide positions required for RF-X binding; several substitutions severely reduced RF-X binding for both natural and recombinant RF-X with the same specificity, and positions important for high-affinity RF-X binding correlate with high levels of class II expression.\",\n      \"method\": \"EMSA with natural and recombinant RF-X protein; systematic single-bp substitutions across the DRA X1 box\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic mutagenesis with both natural and recombinant protein, EMSA, single lab but two forms of the factor used\",\n      \"pmids\": [\"1903200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"The W element (−143 to −123 bp) of the HLA-DRA promoter is a positive transcriptional regulator active in all DR+ cell types (not B-cell-specific), binding proteins W-B1 (ubiquitous) and W-B2 (lymphoid-specific); W/P-dependent activity parallels endogenous DRA transcription but tissue-restricted regulation is not accounted for solely by differential W-protein binding.\",\n      \"method\": \"Transient transfection reporter assays in multiple cell types; EMSA with W-element oligonucleotides; 5′ deletion and substitution analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — reporter assay plus EMSA across multiple cell types, single lab\",\n      \"pmids\": [\"1991973\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"The X-A DNA–protein complex containing proteins of ~22, 32, 82, and 92 kDa (UV cross-linked) is required for HLA-DRA X-box-dependent transcription; this complex is absent in the immunodeficient B-cell mutant 6.1.6 and in some (but not all) patient-derived class II–negative immunodeficiency cells.\",\n      \"method\": \"Transient transfection of DRA promoter-reporter constructs; EMSA; UV cross-linking of proteins to BrdU-substituted probe; comparison of normal and mutant cell extracts\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — UV cross-linking identifies complex components; multiple cell lines tested; single lab\",\n      \"pmids\": [\"1904083\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"In primary astrocytes, IFN-γ regulation of HLA-DRA requires the S, X (specifically X1), and Y elements; IFN-γ induces a novel X-element–binding nuclear factor (IFNEX) in astrocytes that is distinct from previously described factors, suggesting IFNEX mediates IFN-γ–driven class II expression in this primary cell type.\",\n      \"method\": \"Site-specific mutagenesis of DRA promoter; transient transfection reporter assay in primary astrocytes; EMSA with nuclear extracts from IFN-γ–treated astrocytes\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — mutagenesis plus EMSA in primary (non-transformed) cell type, single lab\",\n      \"pmids\": [\"1588050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"TNF-α alone does not activate the HLA-DRA promoter in astrocytes but synergizes with IFN-γ via formation of a novel, slower-migrating DNA–protein complex (TIC-X) at the X element; W, X, and Y elements are all required for this TNF-α enhancement of IFN-γ–induced promoter activity.\",\n      \"method\": \"Transient transfection of DRA-CAT reporter in primary astrocytes ± IFN-γ and/or TNF-α; EMSA with nuclear extracts\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — reporter assay plus EMSA in primary astrocytes, single lab, two cytokine conditions\",\n      \"pmids\": [\"1454841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"T-cell activation induces strong HLA-DRA promoter activity from a proximal 43-bp TATTA-containing region in primary (non-transformed) T lymphocytes; mutation of the TATTA motif greatly reduces expression; addition of X and Y elements augments early activation response but paradoxically suppresses promoter function in already-activated DR+ T cells, revealing a cell-state-dependent switch.\",\n      \"method\": \"Transient transfection of DRA-CAT reporter constructs in primary human T lymphocytes stimulated by mitogens or antigens; TATTA mutagenesis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — mutagenesis plus transfection in primary (non-transformed) cells, single lab\",\n      \"pmids\": [\"1448091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"hXBP-1, a b-ZIP transcription factor, regulates HLA-DRA through the X2 box; the hXBP-1 promoter itself contains an hX2 element identical to the X2 site in the DRA promoter, and two of four protein complexes binding the hXBP-1 hX2 site cross-compete with DRA X2-binding complexes, indicating an autoregulatory loop.\",\n      \"method\": \"EMSA cross-competition experiments; mutagenesis of hX2 site; DRA promoter mapping; hybrid cell mapping of hXBP-1 loci\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — EMSA cross-competition plus mutagenesis, single lab\",\n      \"pmids\": [\"8349596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"TRAX1, affinity-purified from HeLa nuclear extracts, is a novel X1-box-binding transcriptional activator of HLA-DRA (~40 kDa by UV cross-linking); it contacts the 5′ end of the X1 sequence (positions −109/−108) with hypersensitive sites at −114/−113/−97, a distinct footprint from RFX1, RFX, NF-Xc, and NF-X; it activates the HLA-DRA promoter in an in vitro transcription assay.\",\n      \"method\": \"Affinity purification from HeLa nuclear extracts; EMSA; UV cross-linking; methylation interference footprinting; in vitro transcription assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — affinity purification, in vitro transcription assay, UV cross-linking, and footprinting in a single study; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"7799935\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"In vitro transcription from the HLA-DRA promoter is completely dependent on the Y box; deletion of the Y box reduces transcription by 95%; the DRA octamer element does not utilize OTF-2 in a manner analogous to immunoglobulin promoters despite OTF-2 being present in B-cell extracts.\",\n      \"method\": \"Cell-free in vitro transcription assay using B-cell and HeLa nuclear extracts; 5′ deletion and internal deletion of Y box and octamer\",\n      \"journal\": \"Tissue antigens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro transcription assay with deletion constructs, single lab, single method\",\n      \"pmids\": [\"2278044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"A 3′ untranslated region signal in HLA-DRA mRNA mediates nuclear retention; deletion of this region abrogates binding of compartmentalized nuclear/cytoplasmic proteins and releases HLA-DRA mRNA into the cytoplasm; the pattern of these mRNA-binding proteins differs between cell types (Raji vs. Ntera-2) and is modulated by retinoic acid.\",\n      \"method\": \"Transient transfection of DRA constructs with 3′ UTR deletions; nuclear/cytoplasmic RNA fractionation; RNA–protein binding assays with compartmentalized extracts\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — transfection with deletion constructs plus fractionation and RNA-protein binding across multiple cell types, single lab\",\n      \"pmids\": [\"8028004\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Oct-1 represses IFN-γ inducibility of the endogenous HLA-DRA gene in Rb-defective tumor cells by occupying the HLA-DRA promoter and forming a repressive complex (DRAN) that blocks NF-Y access to the promoter; trichostatin A (HDAC inhibitor) converts the promoter to a transcriptionally competent state and displaces Oct-1.\",\n      \"method\": \"Oct-1 antisense transformants; chromatin immunoprecipitation (ChIP) of endogenous HLA-DRA promoter; in vitro DNA–protein binding (DRAN complex analysis); TSA treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP of endogenous gene plus antisense functional knockdown plus in vitro complex characterization, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"15105429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TLR-triggered (CpG-DNA and LPS) HLA-DRA expression in human B cells requires NF-κB activation at the DRA promoter in addition to CIITA; dominant-negative CIITA and CIITA siRNA show CIITA alone is insufficient for maximal TLR-induced expression, whereas NF-κB is dispensable for IFN-γ–induced class II expression.\",\n      \"method\": \"Dominant-negative CIITA expression; CIITA siRNA knockdown; NF-κB pathway inhibition; EMSA; chromatin immunoprecipitation (ChIP); promoter-reporter mutant analysis\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple approaches (DN mutant, siRNA, ChIP, EMSA, mutagenesis) in a single study, single lab\",\n      \"pmids\": [\"16619292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Active transcription of HLA-DRA is accompanied by reduced nucleosome density at the proximal regulatory region and distinct distributions of histone acetylation and methylation marks throughout the gene; most modifications depend on RFX or CIITA binding to the proximal regulatory region; once established after IFN-γ induction, modifications persist through multiple cell divisions (epigenetic memory). Components of MLL methyltransferase (MLL1, ASH2L, RbBP5—some CIITA-independent) and GCN5-containing acetyltransferase complexes (ATAC and STAGA) are recruited across the gene.\",\n      \"method\": \"Dual crosslinking ChIP; ChIP-seq-like profiling of multiple histone marks; RFX and CIITA mutant B-cell lines; cell division tracking after stimulus removal; identification of complex components by ChIP\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP across multiple marks and mutant cell lines, multiple orthogonal approaches in a single study, single lab\",\n      \"pmids\": [\"22701520\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Recombinant HLA-DRA1*0101/DRB1*0401 heterodimers expressed in Drosophila S2 cells are functional: they present peptides to DRB1*0401-restricted T cells, bind peptide with similar specificity and affinity to human B-cell-derived molecules, and can be stabilized by high-affinity peptide; they show decreased N-linked glycosylation compared to human-derived molecules but retain antigen-presentation capacity.\",\n      \"method\": \"Drosophila S2 cell expression; flow cytometry; T-cell stimulation assay; SDS-PAGE stability assay ± peptide; peptide-binding assay\",\n      \"journal\": \"Tissue antigens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution in heterologous system with functional T-cell assay and peptide-binding measurements; single lab but multiple orthogonal functional readouts\",\n      \"pmids\": [\"9510368\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Expression of HLA-DRA in thymic epithelial cells (without bone-marrow-derived APC expression) is sufficient to drive clonal deletion of superantigen-reactive T cells bearing TCRβ-V5 and -V11, and to induce tolerance to DR-alpha-derived processed peptide/I-Ab complexes, likely via clonal deletion.\",\n      \"method\": \"Transgenic mouse lines with cell-type-restricted HLA-DRA expression (thymic epithelium only vs. all APC); TCR Vβ repertoire analysis; T-cell tolerance assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined transgenic lines with restricted expression, multiple T-cell assays, clear genetic epistasis; single lab\",\n      \"pmids\": [\"8100779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Transgenic DR-alpha/E-beta mixed isotype molecules efficiently interact with Mtv-7 superantigen to delete V-beta-6+ and V-beta-7+ T cells; deletion of V-beta-11+ T cells with Mtv-8/9 was less efficient than with H-2Ea transgenes, demonstrating that the alpha-chain identity influences superantigen interaction but the beta-chain identity is the critical determinant.\",\n      \"method\": \"HLA-DRA transgenic mice on various mouse Mtv-bearing backgrounds; TCR Vβ repertoire analysis by flow cytometry and Southern blot\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — comparative transgenic analysis across multiple Mtv integrants; single lab\",\n      \"pmids\": [\"8244778\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The retinoblastoma protein (Rb) is required for IFN-γ induction of HLA-DRA (and other class II) mRNA in non-small-cell lung carcinoma cells; RB reconstitution rescues DRB inducibility but not DRA inducibility in H2009 subclones, explaining the lack of surface HLA-DR expression, and this Rb requirement operates independently of Rb's role in inhibiting apoptosis.\",\n      \"method\": \"RB reconstitution in RB-defective H2009 tumor cell subclones; Northern blot analysis of class II mRNAs; surface HLA-DR flow cytometry; CIITA mRNA analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — RB reconstitution with multiple mRNA and surface protein readouts, comparison to a second tumor line; single lab\",\n      \"pmids\": [\"8786310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A splice-acceptor variant (rs8084) in HLA-DRA mediates transcription of a short HLA-DRA isoform (sHLA-DRA) lacking 25 amino acids in the extracellular domain; molecular dynamics simulations predict structural refolding affecting stability and trafficking; experimentally, sHLA-DRA cannot reach the cell surface independently but is retained in the ER for degradation, yet can be transported to the membrane via binding to the peptide-binding site of canonical full-length HLA heterodimers.\",\n      \"method\": \"Splice-variant identification; molecular dynamics simulations; cellular fractionation/trafficking assays; co-expression with canonical HLA-DR heterodimers; flow cytometry\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — experimental trafficking assays plus MD simulations; single lab, multiple methods but MD is computational\",\n      \"pmids\": [\"32986852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The short HLA-DRA isoform (sHLA-DRA) binds to the outer domain of the HLA-DR2 peptide-binding site via a loop region (residues R69–G83) exposed only in the short isoform; the critical residue F76 mediates this interaction (experimentally validated); sHLA-DRA allosterically modifies the peptide-binding pocket conformation of canonical HLA-DR2 heterodimers.\",\n      \"method\": \"Atomistic molecular dynamics simulations; mutational validation of F76 residue; functional binding assays\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — MD simulations with experimental mutagenesis validation of critical residue; single lab\",\n      \"pmids\": [\"35218721\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cuproptosis upregulates HLA-DRA expression at the transcriptional level in a dose-dependent manner in ccRCC cells by inducing reactive oxygen species (ROS) production; high HLA-DRA expression promotes chemokine (CCL5, CXCL9, CXCL10) expression in the tumor microenvironment, enhances CD4+ and CD8+ T-cell infiltration, and synergizes with anti-PD-1 immunotherapy to suppress tumor growth in vivo.\",\n      \"method\": \"In vitro cuproptosis induction in ccRCC cells; dose-response RT-PCR/Western blot for HLA-DRA; siRNA knockdown; chemokine ELISA; in vivo mouse tumor model with anti-PD-1 treatment; flow cytometry for T-cell infiltration\",\n      \"journal\": \"Pharmaceuticals (Basel, Switzerland)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — in vitro mechanistic assays plus in vivo validation; single lab\",\n      \"pmids\": [\"38931345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"siRNA knockdown of HLA-DRA in human valvular interstitial cells (VICs) under osteogenic stimulation reduces mineral deposition, alkaline phosphatase (ALP) activity, and VIC proliferation, indicating HLA-DRA functionally drives osteogenic remodeling in vitro.\",\n      \"method\": \"siRNA knockdown of HLA-DRA in human VICs; osteogenic stimulation; Alizarin Red S staining; ALP activity assay; CCK-8 proliferation assay; RT-qPCR; Western blot\",\n      \"journal\": \"Journal of computer-aided molecular design\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single study, siRNA knockdown with cellular phenotype but no pathway placement beyond observation\",\n      \"pmids\": [\"41721874\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"HLA-DRA overexpression in nasal mucosal epithelial cells increases radiosensitivity (reduced clonogenic survival, enhanced apoptosis, suppressed proliferation after irradiation) and elevates IFN-γ and IL-6 production, which activates JAK-STAT signaling; HLA-DRA knockout has the opposite effects, implicating HLA-DRA in regulating the JAK-STAT inflammatory pathway in irradiated epithelial cells.\",\n      \"method\": \"CRISPR/Cas9 HLA-DRA knockout and overexpression in nasal mucosal epithelial cells; X-ray irradiation; colony formation assay; CCK-8; flow cytometry (apoptosis); RT-qPCR; ELISA; Western blot for STAT phosphorylation\",\n      \"journal\": \"Zhonghua er bi yan hou tou jing wai ke za zhi\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — CRISPR KO and OE with multiple orthogonal assays and pathway identification; single lab\",\n      \"pmids\": [\"41956771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Nuclear factor NF-Y binds to Y-box sequences in both the proximal promoter and the far-upstream region of HLA-DRA (Y′ box), as demonstrated by antibody supershift in gel-retardation assays; similar proteins bind to Y and Y′ boxes and to X and X′ boxes, supporting a model in which protein dimerization across these elements induces a DNA stem-loop bringing the far-upstream and proximal-promoter regions into proximity.\",\n      \"method\": \"DNase I footprinting; gel retardation (EMSA); antibody supershift for NF-Y identification\",\n      \"journal\": \"Biochimie\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — EMSA and footprinting identifying NF-Y at Y′ box; single lab, in vitro only, no functional (transcription) assay\",\n      \"pmids\": [\"10385003\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HLA-DRA encodes the invariant α-chain of the HLA-DR class II MHC heterodimer; its transcription is controlled by a promoter module containing W, X1, X2, and Y cis-elements that recruit a hierarchy of trans-acting factors—including RF-X (occupying X1 and establishing chromatin accessibility), CIITA (coordinating H3/H4 histone acetyltransferase activities via MLL and GCN5/STAGA complexes), NF-Y (Y-box), Oct-1 (repressor in Rb-defective cells), NF-κB (required for TLR-mediated but not IFN-γ-mediated induction), and TRAX1 (a novel X1-binding activator)—with IFN-γ induction acting specifically by strengthening X-box protein–DNA interactions; a splice-acceptor variant generates a short isoform that is ER-retained and degraded but can reach the membrane by binding the outer peptide-binding site of canonical HLA-DR heterodimers, where it allosterically modifies the peptide-binding pocket.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"HLA-DRA encodes the invariant α-chain of the HLA-DR class II MHC heterodimer, which pairs with a DRB β-chain to present peptide antigens to CD4+ T cells; recombinant DRA/DRB heterodimers reconstituted in heterologous cells bind peptide with native specificity and affinity and productively stimulate restricted T cells [#20], and DRA-driven surface class II in thymic epithelium is sufficient to delete superantigen- and DR-peptide-reactive T cells, establishing a role in central tolerance [#21]. The peptide-presenting α-chain identity modulates, but does not dictate, superantigen engagement, which is governed primarily by the β-chain [#22]. The dominant theme of the corpus is transcriptional control of HLA-DRA through a conserved proximal module of W, X1, X2, and Y cis-elements that must remain precisely spaced and helically phased to assemble a single cooperative complex required for both constitutive and inducible expression [#3, #4]. RF-X occupies the X1 box, correlating with class II DNase I hypersensitivity and lost in class II–deficient immunodeficiency mutants, marking it as necessary but not sufficient for expression [#6, #7], while additional X-box-region factors (X2BP, hXBP-1, TRAX1) and the Y-box factor NF-Y act through the same module [#1, #13, #14, #15]. CIITA serves as the master coordinator, recruiting distinct histone acetyltransferase activities—directing H4 (Lys8) and H3 acetylation through separable domains—and, together with RFX, establishing reduced nucleosome density and heritable histone modification patterns across the locus [#0, #19]. IFN-γ induces expression specifically by strengthening protein–DNA contacts at the X1/X2 boxes [#2], with cell-type-specific and stimulus-specific factors layered on top: an astrocyte IFN-γ–induced X-element factor and TNF-α synergy complex [#10, #11], an Rb requirement for DRA induction with Oct-1 acting as a repressor that excludes NF-Y in Rb-defective cells [#17, #23], and an NF-κB requirement specific to TLR-driven (but not IFN-γ–driven) induction [#18]. Post-transcriptionally, a 3′ UTR signal mediates nuclear retention of HLA-DRA mRNA [#16], and a splice-acceptor variant (rs8084) produces a short ER-retained isoform that lacks 25 extracellular residues and, rather than reaching the surface alone, binds the outer peptide-binding domain of canonical HLA-DR heterodimers via an exposed loop (F76) and allosterically reshapes the peptide-binding pocket [#24, #25]. In disease and tissue contexts, HLA-DRA expression is induced by cuproptosis-driven ROS and promotes T-cell-infiltrating chemokine production that synergizes with anti-PD-1 therapy in ccRCC [#26], and modulates JAK-STAT inflammatory signaling and radiosensitivity in irradiated epithelial cells [#28].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Establishing which trans-acting factor licenses class II chromatin addressed why some cells fail to express HLA-DRA despite an intact promoter.\",\n      \"evidence\": \"DNase I hypersensitivity mapping and RF-X binding across normal B cells, class II–deficient mutants, and fibroblasts\",\n      \"pmids\": [\"2467188\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"RF-X binding necessary but not sufficient for expression\", \"additional factors enabling fibroblast/IFN-γ competence not identified\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Dissecting the proximal promoter elements clarified that the Y box and X-box-binding proteins exert non-redundant positive and negative control over transcription.\",\n      \"evidence\": \"Cell-free in vitro transcription with Y-box/octamer deletions; competition EMSA mapping W and V elements to X-box-binding proteins\",\n      \"pmids\": [\"2278044\", \"2120707\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"identity of the shared X/W/V-binding proteins not resolved\", \"octamer factor usage distinct from immunoglobulin promoters but mechanism unclear\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Mapping the precise nucleotides and protein complexes at the X and W boxes defined the molecular grammar of factor recognition and linked binding affinity to expression level.\",\n      \"evidence\": \"Single-bp substitutions with natural and recombinant RF-X; EMSA distinguishing RFX (X1) from X2BP (X2); UV cross-linking of the X-A complex; W-element reporter/EMSA across cell types\",\n      \"pmids\": [\"1903200\", \"1956787\", \"1904083\", \"1991973\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"molecular identities of X-A complex subunits (22/32/82/92 kDa) not cloned\", \"basis for tissue-restricted expression beyond differential binding unexplained\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Systematic mutagenesis and IFN-γ footprinting resolved how a single cooperative complex on geometrically constrained elements drives both constitutive and inducible expression.\",\n      \"evidence\": \"Single-bp, spacing, and helical-phasing mutants in B cells and IFN-γ-treated fibroblasts; in vivo genomic footprinting ± IFN-γ; astrocyte IFNEX and TNF-α/IFN-γ synergy (TIC-X) EMSA\",\n      \"pmids\": [\"1560213\", \"1331098\", \"1502171\", \"1588050\", \"1454841\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"IFNEX and TIC-X factors not molecularly identified\", \"structural model of the X/Y stem-loop complex not determined\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Functional and genetic tests established the protein product's role in antigen presentation, central tolerance, and the relative contribution of the α-chain to superantigen engagement.\",\n      \"evidence\": \"HLA-DRA transgenic mice with tissue-restricted expression; TCR Vβ repertoire and tolerance assays; hXBP-1 X2 cross-competition EMSA\",\n      \"pmids\": [\"8100779\", \"8244778\", \"8349596\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"mechanism of thymic-epithelial clonal deletion incompletely defined\", \"extent of hXBP-1 autoregulatory contribution to DRA in vivo unquantified\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Affinity purification of a novel X1-binding activator extended the cast of transcription factors converging on the X box.\",\n      \"evidence\": \"Affinity purification from HeLa extracts; footprinting, UV cross-linking, and in vitro transcription showing TRAX1 activation\",\n      \"pmids\": [\"7799935\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"TRAX1 gene identity and interplay with RFX/CIITA not established\", \"in vivo requirement not tested\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Identifying an Rb requirement and a 3′ UTR retention signal added a tumor-suppressor input and a post-transcriptional control layer to DRA regulation.\",\n      \"evidence\": \"RB reconstitution in RB-defective tumor cells with mRNA/surface readouts; 3′ UTR deletion with nuclear/cytoplasmic fractionation and RNA-protein binding\",\n      \"pmids\": [\"8786310\", \"8028004\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"molecular step at which Rb acts on DRA induction unclear\", \"identity of the 3′ UTR-binding retention proteins unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defining Oct-1 as a repressor that excludes NF-Y explained how Rb-defective cells silence inducible HLA-DRA.\",\n      \"evidence\": \"ChIP of endogenous promoter, Oct-1 antisense knockdown, DRAN complex analysis, and TSA treatment\",\n      \"pmids\": [\"15105429\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"link between Rb status and Oct-1 recruitment not fully mechanistic\", \"generality beyond Rb-defective tumor cells untested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Distinguishing TLR/NF-κB-dependent from IFN-γ-dependent induction showed CIITA is necessary but not sufficient for all activation routes.\",\n      \"evidence\": \"Dominant-negative CIITA, CIITA siRNA, NF-κB inhibition, ChIP, and EMSA in human B cells\",\n      \"pmids\": [\"16619292\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"how NF-κB cooperates physically with CIITA/RFX at the promoter unresolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Profiling chromatin state across the locus integrated RFX/CIITA factor binding with specific histone-modifying complexes and demonstrated heritable epigenetic memory of induction.\",\n      \"evidence\": \"Dual-crosslinking ChIP of multiple histone marks, RFX/CIITA mutant B-cell lines, MLL and GCN5 complex component detection, cell-division tracking\",\n      \"pmids\": [\"22701520\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"mechanism maintaining marks through division not defined\", \"CIITA-independent MLL recruitment route unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Characterizing a splice-acceptor variant revealed a non-canonical short isoform that piggybacks on full-length heterodimers and allosterically modulates peptide binding.\",\n      \"evidence\": \"Splice-variant identification, trafficking/fractionation assays, co-expression with canonical heterodimers, MD simulations, and F76 mutational validation\",\n      \"pmids\": [\"32986852\", \"35218721\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"functional/immunological consequence of pocket allostery in vivo not measured\", \"structural claims rest substantially on MD simulation\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Linking HLA-DRA to tumor immunity and tissue remodeling positioned its expression as a functional driver of inflammatory and disease phenotypes.\",\n      \"evidence\": \"Cuproptosis/ROS induction with chemokine and T-cell-infiltration readouts and anti-PD-1 in vivo; CRISPR KO/OE radiosensitivity and JAK-STAT analysis; siRNA osteogenesis assays\",\n      \"pmids\": [\"38931345\", \"41956771\", \"41721874\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"whether phenotypes depend on antigen presentation versus non-canonical roles unresolved\", \"osteogenesis finding is single low-confidence study without pathway placement\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular identities of several X-box-region factors (X-A complex, IFNEX, TIC-X) and the structural architecture of the cooperative W/X/Y enhanceosome remain undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"no cloned identity for the UV-crosslinked X-A complex subunits\", \"no high-resolution structure of the assembled promoter complex\", \"in vivo contribution of TRAX1 and hXBP-1 not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [20, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [20, 24]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [20, 21]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 3, 6, 19]}\n    ],\n    \"complexes\": [\n      \"HLA-DR class II MHC heterodimer\"\n    ],\n    \"partners\": [\n      \"RFX\",\n      \"CIITA\",\n      \"NFY\",\n      \"POU2F1\",\n      \"XBP1\",\n      \"RB1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}